PARK MEDI WORLD LIMITED PARKHOSPS NSEPHARMA

Healthcare · Medical Care Facilities · India

https://www.parkhospital.in

Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.

Market & Price

Market Cap

₹12,462.93 Cr

Current Price

₹288.54

High / Low (52W)

₹288.54 / ₹143.92

Beta

Valuation

Stock P/E

42.00

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹50.79

Price to Book

5.68

P/S

7.42

EV/EBITDA

25.89

Dividend Yield

Profitability & Returns

ROCE

18.10%

ROE

16.94%

ROA

9.65%

Profit Margin

15.37%

Op Margin

23.86%

EPS (Latest Qtr)

₹1.64

EPS (TTM)

₹6.87

Balance Sheet & Liquidity

Debt/Equity

0.17

Quick Ratio

1.94

Current Ratio

2.06

Debt

₹364.19 Cr

Total Assets

₹2,813.15 Cr

Current Assets

₹1,087.79 Cr

Working Capital

₹558.89 Cr

Ownership

Promoter Holding

83.94%

Chg in Prom Hold

FII / Inst Holding

6.14%

Chg in FII Hold

-0.07%

Financial Snapshot

Enterprise Value

₹11,502.25 Cr

Total Revenue (TTM)

₹1,679.36 Cr

EBITDA

₹444.32 Cr

Free Cash Flow

₹161.55 Cr

Operating Cash Flow

₹329.09 Cr

Shares Outstanding

₹43.19 Cr

Gross Margin

63.13%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

10.27%

Profit 5Y

5.52%

Revenue (YoY)

30.10%

Earnings (YoY)

30.90%

PROS

Compounding revenue at 10.3% over 5 years.
Generates positive free cash flow.

CONS

RSI at 78 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PARKHOSPS PARK MEDI WORLD LIMITED NSEPHARMA	288.54	42.00	₹12,462.93 Cr	-	18.10%	16.94%	10.27%	5.52%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Dec 2025	Mar 2026
Revenue	348.13 Cr	353.92 Cr	409.97 Cr	460.41 Cr
Cost of Revenue	143.32 Cr	135.97 Cr	158.72 Cr	165.79 Cr
Gross Profit	204.81 Cr	217.95 Cr	251.25 Cr	294.62 Cr
Operating Expenses	137.03 Cr	145.04 Cr	167.14 Cr	184.76 Cr
Operating Income	67.78 Cr	72.91 Cr	84.11 Cr	109.86 Cr
EBITDA	97.56 Cr	97.00 Cr	108.51 Cr	134.87 Cr
Interest Expense	15.73 Cr	15.64 Cr	14.95 Cr	13.97 Cr
Pretax Income	66.81 Cr	65.83 Cr	78.27 Cr	103.39 Cr
Tax Provision	21.16 Cr	13.47 Cr	25.42 Cr	26.61 Cr
Net Income	45.59 Cr	44.84 Cr	50.78 Cr	70.86 Cr
Diluted EPS	1.06	1.04	1.35	1.64

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	1,252.38 Cr	1,229.06 Cr	1,393.57 Cr	1,679.36 Cr
Cost of Revenue	411.50 Cr	472.88 Cr	557.82 Cr	619.20 Cr
Gross Profit	840.87 Cr	756.18 Cr	835.75 Cr	1,060.15 Cr
Operating Expenses	468.97 Cr	486.47 Cr	521.66 Cr	678.29 Cr
Operating Income	371.90 Cr	269.72 Cr	314.10 Cr	381.86 Cr
EBITDA	404.74 Cr	338.27 Cr	403.40 Cr	475.93 Cr
Interest Expense	49.20 Cr	69.53 Cr	60.84 Cr	58.88 Cr
Pretax Income	315.03 Cr	218.16 Cr	285.67 Cr	354.58 Cr
Tax Provision	86.84 Cr	66.16 Cr	70.23 Cr	81.03 Cr
Net Income	219.67 Cr	153.49 Cr	201.64 Cr	258.12 Cr
Diluted EPS	5.09	3.55	4.67	6.87

Compounded Sales Growth

5 Years:	10.27%
1 Year:	30.10%

Compounded Profit Growth

5 Years:	5.52%
1 Year:	30.90%

Stock Price Performance

1 Year:	+95.03%
6 Months:	-
3 Months:	+49.53%
1 Month:	+25.17%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	1,592.82 Cr	1,912.10 Cr	2,133.70 Cr	2,813.15 Cr
Current Assets	818.56 Cr	943.02 Cr	1,033.66 Cr	1,087.79 Cr
Cash & Equivalents	100.05 Cr	76.63 Cr	103.00 Cr	236.85 Cr
Inventory	1.68 Cr	2.20 Cr	2.54 Cr	2.90 Cr
Receivables	576.36 Cr	510.96 Cr	613.50 Cr	593.49 Cr
Total Liabilities	862.85 Cr	976.59 Cr	1,007.43 Cr	708.85 Cr
Current Liabilities	521.38 Cr	526.59 Cr	556.12 Cr	528.90 Cr
Long Term Debt	318.77 Cr	391.02 Cr	384.25 Cr	18.96 Cr
Total Debt	575.68 Cr	686.71 Cr	682.07 Cr	364.19 Cr
Total Equity	686.56 Cr	882.79 Cr	1,069.58 Cr	2,021.98 Cr
Shares Outstanding	43.19 Cr	43.19 Cr	43.19 Cr	43.19 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	195.03 Cr	361.44 Cr	215.38 Cr	329.09 Cr
Investing Cash Flow	-179.63 Cr	-254.55 Cr	-100.15 Cr	-333.45 Cr
Financing Cash Flow	1.51 Cr	-130.30 Cr	-88.86 Cr	120.83 Cr
Capital Expenditure	-98.43 Cr	-71.45 Cr	-145.12 Cr	-119.69 Cr
Free Cash Flow	96.60 Cr	289.98 Cr	70.27 Cr	209.41 Cr
Net Change in Cash	16.91 Cr	-23.42 Cr	26.38 Cr	116.48 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	67.1%	61.5%	60.0%	63.1%
Operating Margin %	29.7%	21.9%	22.5%	22.7%
Net Margin %	17.5%	12.5%	14.5%	15.4%
ROE %	32.0%	17.4%	18.9%	12.8%
ROCE %	34.7%	19.5%	19.9%	16.7%

Shareholding Pattern

Insiders

83.94%

Institutions

6.14%

Public Float

38.21%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PARKHOSPS

No recent headlines available.

PARKHOSPS · Healthcare